Recommended

GSK appoints new CEO
New webinar | Addressing the time-to-result challenge posed by short shelf-life radiopharmaceuticals, register today
Genmab acquires biotech Merus for $8bn
US FDA licensing first for IL-23 inhibitor to treat paediatric psoriasis
Teva makes progress on API business divestment
Takeda to move away from cell therapy
news

Retail prices on several anti-cancer medications slashed

7
SHARES

The retail prices of some anti-cancer drugs have been cut by 87 percent by the drug price control authority in India.

After reviewing data collected from drug manufacturers, The National Pharmaceutical Pricing Authority’s (NPPA) 15 May memorandum has bought nine anti-cancer drugs in its price control framework.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

Some of the drugs included in this price cut are:

  • Pemetrexed (brand name Pemxcel) – down to Rs 2800 from Rs 22,000 (500mg); and Rs 800 from Rs 7,700 (100mg)
  • Erlotinib tablets (brand name Erlotaz) – down to Rs 1840 from Rs 6,600 (100mg); and Rs 2,400 from Rs 8,800 (150mg)
  • Epirubicin (brand name Epichlor) – down to Rs 276.8 from Rs 561 (10mg); and Rs 561 from Rs 960 (50mg)
  • Everolimus (brand name Lanolimus) – down to Rs 406 from Rs 739 (0.25mg); and Rs 726 from Rs 1,452 (0.5 mg)
  • Leuprolide acetate hormonal therapy injection (brand name Leuprogon Depot) – down to Rs 2,650 from Rs 3,990.

“Most of these are commonly used in several cancer therapies,” said Dr T Raja, senior oncologist, Apollo Speciality Hospital. “The cost cut will be extremely beneficial to patients, particularly those who spend out of their pocket.”

This is the second time that the NPPA has announced a price cut on anti-cancer drugs since March 2019. In February it brought 42 non-scheduled anti-cancer drugs under price control, capping a trade margin of 30 percent through trade margin rationalisation. This resulted in at least 72 formulations and over 390 brands having reduced costs.

Heath industry spokespersons have said that drug manufacturers have been asked to not cut down on production volumes following this memorandum.

Share via
Share via